argenex SE (NASDAQ:ARGX) Given Consensus Recommendation of "Moderate Buy" by Analysts
Argenex SE (NASDAQ:ARGX) has received a "Moderate Buy" consensus rating from 24 brokerages, with a 12-month target price of $907.67. Analysts have varied ratings, including hold, buy, and strong buy. Recent price targets range from $850 to $1,070. Institutional investors own 60.32% of the stock. Argenex reported $4.40 EPS for the quarter, surpassing estimates, with $1.12 billion revenue. The company develops therapies for autoimmune diseases globally.
Shares of argenex SE (NASDAQ:ARGX - Get Free Report) have been given an average rating of "Moderate Buy" by the twenty-four brokerages that are currently covering the company, MarketBeat Ratings reports. Four research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $907.6667.
- 3 Healthcare Pathbreakers With Long-Term Tailwinds
Several analysts recently weighed in on the stock. Guggenheim reiterated a "buy" rating and issued a $1,070.00 price target on shares of argenex in a report on Thursday, September 18th. Wolfe Research reaffirmed a "peer perform" rating on shares of argenex in a research report on Monday, November 24th. Zacks Research cut shares of argenex from a "strong-buy" rating to a "hold" rating in a research report on Tuesday, October 21st. Wedbush increased their price target on shares of argenex from $880.00 to $1,000.00 and gave the stock an "outperform" rating in a research note on Friday, November 14th. Finally, Royal Bank Of Canada raised their target price on argenex from $850.00 to $860.00 and gave the company an "outperform" rating in a research note on Friday, October 31st.
Get Our Latest Analysis on argenex
Hedge Funds Weigh In On argenex
- 5 medical stocks growing earnings by triple digits
Institutional investors and hedge funds have recently made changes to their positions in the business. Ameriflex Group Inc. bought a new stake in shares of argenex in the 3rd quarter worth approximately $32,000. Sunbelt Securities Inc. purchased a new position in argenex during the third quarter valued at $36,000. WPG Advisers LLC bought a new stake in argenex in the first quarter worth $37,000. Brooklyn Investment Group boosted its holdings in argenex by 102.7% in the first quarter. Brooklyn Investment Group now owns 75 shares of the company's stock worth $44,000 after acquiring an additional 38 shares in the last quarter. Finally, Bessemer Group Inc. grew its stake in shares of argenex by 276.5% in the third quarter. Bessemer Group Inc. now owns 64 shares of the company's stock worth $47,000 after acquiring an additional 47 shares during the last quarter. Institutional investors own 60.32% of the company's stock.
argenex Price Performance
Shares of NASDAQ:ARGX opened at $901.17 on Monday. The stock's 50-day moving average is $850.63 and its 200 day moving average is $707.41. The company has a market cap of $55.49 billion, a PE ratio of 38.69, a P/E/G ratio of 0.91 and a beta of 0.36. argenex has a 1 year low of $510.05 and a 1 year high of $934.62.
- Argenx's 28% Surge & Promising Product Propel Investor Confidence
argenex (NASDAQ:ARGX - Get Free Report) last issued its quarterly earnings data on Thursday, October 30th. The company reported $4.40 earnings per share for the quarter, topping analysts' consensus estimates of $4.37 by $0.03. argenex had a return on equity of 29.78% and a net margin of 41.58%.The firm had revenue of $1.12 billion for the quarter, compared to analyst estimates of $1.07 billion. Analysts expect that argenex will post 3.13 EPS for the current fiscal year.
argenex Company Profile
(Get Free Report)argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren's syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.
Recommended Stories
- Five stocks we like better than argenex
- Canada Bond Market Holiday: How to Invest and Trade
- Rubrik’s Massive Rebound: Why the Next Leg Higher Could Be Fast
- What Are Dividend Contenders? Investing in Dividend Contenders
- Five Below and Dollar Tree Earnings Signal a Shopper Shift
- Consumer Discretionary Stocks Explained
- Ulta’s Stock May Be Set for a Glow-Up—20% Upside Ahead?
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.
Should You Invest $1,000 in argenex Right Now?
Before you consider argenex, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and argenex wasn't on the list.
While argenex currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
